Earnings Preview: ALX Oncology to Report Financial Results Pre-market on May 08
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
UBS Initiates ALX Oncology(ALXO.US) With Buy Rating, Announces Target Price $1.2
UBS Adjusts ALX Oncology Price Target to $1.20 From $2.20, Maintains Buy Rating
LifeSci Capital Reaffirms Their Hold Rating on ALX Oncology Holdings (ALXO)
ALX Oncology's CD47-blocker and Keytruda Combo Fails in Two Phase II Trials
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care
ALX Oncology Announces Encouraging Final Results From Phase 1 Trial Evaluating Evorpacept in Combination With Standard-of-Care Treatment in Patients With B-cell Non-Hodgkin Lymphoma
Express News | ALX Oncology Announces Encouraging Final Results From Phase 1 Trial Evaluating Evorpacept in Combination With Standard-of-Care Treatment in Patients With B-Cell Non-Hodgkin Lymphoma
ALX Oncology Falls on Mid-stage Trial Setback for Lead Asset
ALX Oncology Announces ASPEN-03 And ASPEN-04 Phase 2 Trials Evaluating Evorpacept With A Checkpoint Inhibitor For The Treatment Of Head And Neck Cancers Did Not Meet Primary Endpoints
Express News | ALX Oncology Reports Aspen-03 and Aspen-04 Phase 2 Trials Evaluating Evorpacept With a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
Express News | ALX Oncology Holdings Inc - to Start Phase 1 Trial for Alx2004 in Mid-2025
Express News | ALX Oncology Receives Ind Clearance From U.S. FDA for Alx2004, a Novel Egfr-Targeted Antibody-Drug Conjugate
ALX Oncology Receives IND Clearance From U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
LifeSci Capital Maintains ALX Oncology(ALXO.US) With Hold Rating
ALX Oncology Holdings: Balancing Growth Potential and Uncertainty With a Hold Rating
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Stifel Maintains ALX Oncology(ALXO.US) With Hold Rating, Cuts Target Price to $1.5